To read the full story, subscribe or sign in.

Redx snags potential $377M deal with Astrazeneca for fibrosis-targeting RXC-006

Aug. 4, 2020

LONDON – Redx Pharma plc is in the process of handing its RXC-006 program over to Astrazeneca plc, after signing a potential $377 million development and commercialization deal for the porcupine inhibitor in the treatment of fibrotic disease.

BioWorld Deals and M&A Genitourinary/sexual function Respiratory

Today's news in brief

BioWorld

BioWorld briefs for May 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 13, 2025.

FDA shift from animal testing fuels organoid, organ-on-chip demand

BioWorld Science

The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing technologies like organoids and...

AI generated, 3D rendering of protein degradation

AACR 2025: Induced proximity strategy, beyond degraders

BioWorld

Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...

Neuroplastin 65 knockout disrupts visual function by altering the retina

BioWorld Science

Researchers from Tongji University School of Medicine and collaborating institutions have discovered that NP65 plays a crucial role in maintaining normal visual...